Smith & Nephew holds recent gains, shares trade steadily in London
25.06.2026 - 21:14:38 | ad-hoc-news.de
By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 21:13.
Smith & Nephew (GB0009223206) starts Thursday trade with a measured picture on the London Stock Exchange. The medical technology group’s shares recently reacted to a new $500 million buyback and now consolidate ahead of the next quarterly figures, according to the latest trading update from early May 2026.Smith & Nephew first-quarter 2026 trading update on Investegate
What recent numbers show
The most recent first-quarter 2026 trading update reported revenue of $1,501 million, which marked a 6.6 percent increase on a reported basis and 3.1 percent growth on an underlying basis versus the prior year period.Investegate summary of the Q1 2026 trading update The company highlighted that underlying revenue growth reached 4.7 percent when adjusted for daily sales, underpinned primarily by strength in Sports Medicine and Ear, Nose and Throat (ENT) products.
Management also noted that this momentum was partly offset by weaker US knee implant sales, pointing to continued work on portfolio and commercial execution in that segment.Details in the Smith & Nephew trading statement In parallel with the Q1 disclosure, Smith & Nephew announced a new share buyback program of $500 million to be executed over the following twelve months, signaling a clear capital allocation stance.
Thursday’s chart and London listing
On Thursday late morning, Smith & Nephew shares trade around 1,144.50 pence on the London Stock Exchange, based on data from Dublin-based broker Davy at 11:21 local time, with the price down 0.69 percent or 8 pence versus the previous close.Davy quote for Smith & Nephew shares The reported intraday range stands between 1,146.50 pence at the day high and 1,134.00 pence at the day low.
Smith & Nephew shares are quoted in the FTSE 100 peer group alongside other large medical technology names and healthcare-oriented constituents, offering investors exposure to surgical devices and implants from a blue-chip London listing.MarketBeat overview of Smith & Nephew on the London market The group also maintains an NYSE listing under the ticker SNN, where the stock last closed at $30.28, reinforcing its international trading footprint for US and European investors.
More news and data on the Smith & Nephew shares
Further company announcements, price data and background on Smith & Nephew can be found in the dedicated topic section and on the group’s investor relations page.
The products behind the shares
Smith & Nephew generates its revenue predominantly from orthopedic reconstruction, sports medicine and trauma devices, as well as advanced wound management products used in hospitals and outpatient care settings.Company overview on Smith & Nephew’s website A concrete example is its portfolio of knee and hip implants, which surgeons use in joint replacement procedures across Europe and the United States.
Where the stock trades today
The Smith & Nephew shares (GB0009223206) trade on 2026-06-25 at 11:21 on the London Stock Exchange at 1,144.50 pence.
Smith & Nephew key share data
- Company: Smith & Nephew plc
- ISIN: GB0009223206
- WKN: 922320
- Ticker: SN (London), SNN (NYSE)
- Trading venue: London Stock Exchange
- Price (as of 2026-06-25, 11:21): 1,144.50 pence
- Market cap: approximately £9.7 billion (as of 2026-06-25)
- Sector / industry: Health Care Equipment & Supplies
- Index membership: FTSE 100
- Next earnings date: 2026-08-04
Disclaimer: This article is for informational purposes only and does not contain investment advice, stock recommendations or personal financial guidance. Figures and dates are based on publicly available sources at the time of writing and may change. Retail investors should consider multiple sources and, where appropriate, seek professional advice before making investment decisions.
